George L. Daikos

Research interests

Publications

• European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

  Clinical Microbiology and Infection · 2021 · https://doi.org/10.1016/j.cmi.2021.11.025

• Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase–Producing Enterobacterales

  Clinical Infectious Diseases · 2020 · https://doi.org/10.1093/cid/ciaa586

• Rationalizing antimicrobial therapy in the ICU: a narrative review

  Intensive Care Medicine · 2019 · https://doi.org/10.1007/s00134-019-05520-5

• International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Ph

  Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2019 · https://doi.org/10.1002/phar.2209

• International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

  Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2019 · https://doi.org/10.1002/phar.2209

• Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment

  Clinical Microbiology and Infection · 2019 · 10.1016/j.cmi.2019.03.014

• Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae

  New England Journal of Medicine · 2019 · 10.1056/nejmc1807634

• Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

  The Lancet Infectious Diseases · 2018 · https://doi.org/10.1016/s1473-3099(18)30099-9

• Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

  Infectious Diseases and Therapy · 2018 · https://doi.org/10.1007/s40121-018-0214-1

• Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

  The Lancet Infectious Diseases · 2018 · https://doi.org/10.1016/s1473-3099(18)30605-4

• Management of KPC-producing Klebsiella pneumoniae infections

  Clinical Microbiology and Infection · 2017 · 10.1016/j.cmi.2017.08.030

• Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

  The Lancet Infectious Diseases · 2017 · https://doi.org/10.1016/s1473-3099(17)30228-1

• Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems

  Antimicrobial Agents and Chemotherapy · 2014 · https://doi.org/10.1128/aac.02166-13

• Treating infections caused by carbapenemase-producing Enterobacteriaceae

  Clinical Microbiology and Infection · 2014 · https://doi.org/10.1111/1469-0691.12697

• Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

  The Lancet Infectious Diseases · 2013 · https://doi.org/10.1016/s1473-3099(13)70190-7

• Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions

  Clinical Microbiology Reviews · 2012 · https://doi.org/10.1128/cmr.05035-11

• Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria

  Clinical Microbiology and Infection · 2012 · 10.1111/j.1469-0691.2012.03823.x

• Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?

  Clinical Microbiology and Infection · 2011 · 10.1111/j.1469-0691.2011.03553.x

• Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control

  Clinical Microbiology and Infection · 2010 · https://doi.org/10.1111/j.1469-0691.2009.03115.x

• Does rituximab increase the incidence of infectious complications? A narrative review

  International Journal of Infectious Diseases · 2010 · 10.1016/j.ijid.2010.03.025

• Prospective Observational Study of the Impact of VIM-1 Metallo-β-Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream Infections

  Antimicrobial Agents and Chemotherapy · 2009 · 10.1128/aac.00782-08

• Adaptive Resistance to Aminoglycoside Antibiotics from First-Exposure Down-Regulation

  The Journal of Infectious Diseases · 1990 · 10.1093/infdis/162.2.414

Current projects

No projects listed.